A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B

Jerid W. Robinson, Deborah M Dickey, Kohji Miura, Toshimi Michigami, Keiichi Ozono, Lincoln R Potter

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

C-type natriuretic peptide (CNP) increases long bone growth by stimulating guanylyl cyclase (GC)-B/NPR-B/NPR2. Recently, a Val to Met missense mutation at position 883 in the catalytic domain of GC-B was identified in humans with increased blood cGMP levels that cause abnormally long bones. Here, we determined how this mutation activates GC-B. In the absence of CNP, cGMP levels in cells expressing V883M-GC-B were increased more than 20 fold compared to cells expressing wild-type (WT)-GC-B, and the addition of CNP only further increased cGMP levels 2-fold. In the absence of CNP, maximal enzymatic activity (Vmax) of V883M-GC-B was increased 15-fold compared to WT-GC-B but the affinity of the enzymes for substrate as revealed by the Michaelis constant (Km) was unaffected. Surprisingly, CNP decreased the Km of V883M-GC-B 10-fold in a concentration-dependent manner without increasing Vmax. Unlike the WT enzyme the Km reduction of V883M-GC-B did not require ATP. Unexpectedly, V883M-GC-B, but not WT-GC-B, failed to inactivate with time. Phosphorylation elevated but was not required for the activity increase associated with the mutation because the Val to Met substitution also activated a GC-B mutant lacking all known phosphorylation sites. We conclude that the V883M mutation increases maximal velocity in the absence of CNP, eliminates the requirement for ATP in the CNP-dependent Km reduction, and disrupts the normal inactivation process.

Original languageEnglish (US)
Pages (from-to)375-382
Number of pages8
JournalBone
Volume56
Issue number2
DOIs
StatePublished - Oct 1 2013

Fingerprint

Guanylate Cyclase
C-Type Natriuretic Peptide
Mutation
Adenosine Triphosphate
Phosphorylation
Bone Development
Missense Mutation
Enzymes
Catalytic Domain

Keywords

  • Achondroplasia
  • Bone growth
  • CGMP
  • Dwarfism
  • Guanylate cyclase
  • Natriuretic peptides

Cite this

A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B. / Robinson, Jerid W.; Dickey, Deborah M; Miura, Kohji; Michigami, Toshimi; Ozono, Keiichi; Potter, Lincoln R.

In: Bone, Vol. 56, No. 2, 01.10.2013, p. 375-382.

Research output: Contribution to journalArticle

Robinson, Jerid W. ; Dickey, Deborah M ; Miura, Kohji ; Michigami, Toshimi ; Ozono, Keiichi ; Potter, Lincoln R. / A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B. In: Bone. 2013 ; Vol. 56, No. 2. pp. 375-382.
@article{f564e4bebc654da88f6536565490e0fe,
title = "A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B",
abstract = "C-type natriuretic peptide (CNP) increases long bone growth by stimulating guanylyl cyclase (GC)-B/NPR-B/NPR2. Recently, a Val to Met missense mutation at position 883 in the catalytic domain of GC-B was identified in humans with increased blood cGMP levels that cause abnormally long bones. Here, we determined how this mutation activates GC-B. In the absence of CNP, cGMP levels in cells expressing V883M-GC-B were increased more than 20 fold compared to cells expressing wild-type (WT)-GC-B, and the addition of CNP only further increased cGMP levels 2-fold. In the absence of CNP, maximal enzymatic activity (Vmax) of V883M-GC-B was increased 15-fold compared to WT-GC-B but the affinity of the enzymes for substrate as revealed by the Michaelis constant (Km) was unaffected. Surprisingly, CNP decreased the Km of V883M-GC-B 10-fold in a concentration-dependent manner without increasing Vmax. Unlike the WT enzyme the Km reduction of V883M-GC-B did not require ATP. Unexpectedly, V883M-GC-B, but not WT-GC-B, failed to inactivate with time. Phosphorylation elevated but was not required for the activity increase associated with the mutation because the Val to Met substitution also activated a GC-B mutant lacking all known phosphorylation sites. We conclude that the V883M mutation increases maximal velocity in the absence of CNP, eliminates the requirement for ATP in the CNP-dependent Km reduction, and disrupts the normal inactivation process.",
keywords = "Achondroplasia, Bone growth, CGMP, Dwarfism, Guanylate cyclase, Natriuretic peptides",
author = "Robinson, {Jerid W.} and Dickey, {Deborah M} and Kohji Miura and Toshimi Michigami and Keiichi Ozono and Potter, {Lincoln R}",
year = "2013",
month = "10",
day = "1",
doi = "10.1016/j.bone.2013.06.024",
language = "English (US)",
volume = "56",
pages = "375--382",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - A human skeletal overgrowth mutation increases maximal velocity and blocks desensitization of guanylyl cyclase-B

AU - Robinson, Jerid W.

AU - Dickey, Deborah M

AU - Miura, Kohji

AU - Michigami, Toshimi

AU - Ozono, Keiichi

AU - Potter, Lincoln R

PY - 2013/10/1

Y1 - 2013/10/1

N2 - C-type natriuretic peptide (CNP) increases long bone growth by stimulating guanylyl cyclase (GC)-B/NPR-B/NPR2. Recently, a Val to Met missense mutation at position 883 in the catalytic domain of GC-B was identified in humans with increased blood cGMP levels that cause abnormally long bones. Here, we determined how this mutation activates GC-B. In the absence of CNP, cGMP levels in cells expressing V883M-GC-B were increased more than 20 fold compared to cells expressing wild-type (WT)-GC-B, and the addition of CNP only further increased cGMP levels 2-fold. In the absence of CNP, maximal enzymatic activity (Vmax) of V883M-GC-B was increased 15-fold compared to WT-GC-B but the affinity of the enzymes for substrate as revealed by the Michaelis constant (Km) was unaffected. Surprisingly, CNP decreased the Km of V883M-GC-B 10-fold in a concentration-dependent manner without increasing Vmax. Unlike the WT enzyme the Km reduction of V883M-GC-B did not require ATP. Unexpectedly, V883M-GC-B, but not WT-GC-B, failed to inactivate with time. Phosphorylation elevated but was not required for the activity increase associated with the mutation because the Val to Met substitution also activated a GC-B mutant lacking all known phosphorylation sites. We conclude that the V883M mutation increases maximal velocity in the absence of CNP, eliminates the requirement for ATP in the CNP-dependent Km reduction, and disrupts the normal inactivation process.

AB - C-type natriuretic peptide (CNP) increases long bone growth by stimulating guanylyl cyclase (GC)-B/NPR-B/NPR2. Recently, a Val to Met missense mutation at position 883 in the catalytic domain of GC-B was identified in humans with increased blood cGMP levels that cause abnormally long bones. Here, we determined how this mutation activates GC-B. In the absence of CNP, cGMP levels in cells expressing V883M-GC-B were increased more than 20 fold compared to cells expressing wild-type (WT)-GC-B, and the addition of CNP only further increased cGMP levels 2-fold. In the absence of CNP, maximal enzymatic activity (Vmax) of V883M-GC-B was increased 15-fold compared to WT-GC-B but the affinity of the enzymes for substrate as revealed by the Michaelis constant (Km) was unaffected. Surprisingly, CNP decreased the Km of V883M-GC-B 10-fold in a concentration-dependent manner without increasing Vmax. Unlike the WT enzyme the Km reduction of V883M-GC-B did not require ATP. Unexpectedly, V883M-GC-B, but not WT-GC-B, failed to inactivate with time. Phosphorylation elevated but was not required for the activity increase associated with the mutation because the Val to Met substitution also activated a GC-B mutant lacking all known phosphorylation sites. We conclude that the V883M mutation increases maximal velocity in the absence of CNP, eliminates the requirement for ATP in the CNP-dependent Km reduction, and disrupts the normal inactivation process.

KW - Achondroplasia

KW - Bone growth

KW - CGMP

KW - Dwarfism

KW - Guanylate cyclase

KW - Natriuretic peptides

UR - http://www.scopus.com/inward/record.url?scp=84881112147&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84881112147&partnerID=8YFLogxK

U2 - 10.1016/j.bone.2013.06.024

DO - 10.1016/j.bone.2013.06.024

M3 - Article

C2 - 23827346

AN - SCOPUS:84881112147

VL - 56

SP - 375

EP - 382

JO - Bone

JF - Bone

SN - 8756-3282

IS - 2

ER -